Should Enveric Biosciences be in Your Stock Portfolio?

: ENVB | Enveric Biosciences Inc. News, Ratings, and Charts

ENVB – Enveric Biosciences (ENVB) garnered significant market attention, announcing its proposed acquisition of MagicMed in May 2021. However, is it smart to bet on the stock now, as it has yet to generate revenue? Let’s find out.

Early-development-stage biosciences company Enveric Biosciences, Inc. (ENVB) is engaged in developing various cannabinoid-based solutions to treat those adversely affected by the side effects of cancer treatments. Its shares soared 10.5% over the past three months on the back of investor optimism surrounding the proposed acquisition of MagicMed Industries Inc. This could help ENVB expand its oncology and central nervous system (CNS) product portfolio.

However, investigations are ongoing against ENVB regarding the proposed acquisition, which could negatively impact the company’s business. The stock has lost 38.3% year-to-date and 60.4% over the past nine months to close Friday’s trading session at $2.63. Moreover, the company is yet to generate revenue, and its losses widened in the second quarter. So, its near-term prospects look uncertain.

Here’s what I think could influence ENVB’s performance in the near term:

Positive Developments

On July 8, ENVB announced that it received approval from the Israeli Ministry of Health to begin the Phase 1/2 portion of its study of its lead asset, EV101, designed to investigate the safety and efficacy of synthetic cannabidiol (CBD) treatment for glioblastoma (GBM). However, the product is not yet approved for marketing. Also, on May 24, ENVB agreed to acquire MagicMed Industries Inc., subject to shareholder approval.

Diverse Biotech announced in March 2021 that it had finalized a strategic transaction with ENVB to license exclusive worldwide development and commercialization rights for five novel compounds to address the side effects of cancer treatments. Also, ENVB launched a strategic development collaboration and exclusive supply agreement with PureForm Global, Inc. in February 2021 to treat pain and inflammation resulting from cancer treatments.

Click here to checkout our Healthcare Sector Report for 2021

Ongoing Investigation

Following ENVB’s announcement of the proposed acquisition of MagicMed, several law firms launched an investigation against ENVB on potential violations of the federal securities laws and breaches of fiduciary duties. Upon completion of the transaction, ENVB’s current shareholders are expected to own roughly 63.4% of the combined company’s common stock. Moreover, class action law firm Purcell Julie & Lefkowitz LLP had launched an investigation against ENVB in January 2021 on a potential breach of fiduciary duty claim involving its board of directors.

Weak Financials

ENVB’s research and development costs increased 1,626.6% year-over-year to $879,843 for the second quarter that ended June 30, 2021. The company’s general and administrative expenses increased 222.3% from the same period last year to $2.31 million. While its loss from operations increased 338.2% year-over-year to $3.36 million, its net loss came in at $908,289, up 11% year-over-year. Its loss per share came in at $0.04 in the quarter compared to a loss of $0.15 in the year-ago period.

POWR Ratings Don’t Indicate Enough Upside

ENVB has an overall grade of C, which equates to a Neutral rating in our POWR Ratings system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.

Our proprietary ratings system also evaluates each stock based on eight different categories. ENVB has a C grade for Growth, consistent with analysts’ expectations that its EPS will remain negative in the current year and next year.

The stock has a D grade for Momentum, in sync with its 18.3% loss over the past six months and 60.4% loss over the past nine months. Moreover, ENVB has a D grade for Stability.

ENVB is ranked #149 out of 510 stocks in the Biotech industry. Click here to see the additional grades for ENVB (Value, Sentiment, and Quality).

Bottom Line

Even though ENVB did not have an impressive stock market debut last year, it has made several advances in developing solutions to treat cancer patients. However, it is still in the early stages of development. Moreover, its near-term prospects look uncertain due to the investigations against it regarding the proposed acquisition of MagicMed. So, it could be wise to wait before adding the stock to your portfolio.

How Does Enveric Biosciences (ENVB) Stack Up Against its Peers?

ENVB has an overall grade of C. However, check out these A-rated (Strong Buy) stocks in the Biotech industry: Sino Biopharmaceutical Limited (SBHMY), QIAGEN N.V. (QGEN), and Takeda Pharmaceutical Company Limited (TAK).


ENVB shares were trading at $2.66 per share on Tuesday morning, up $0.03 (+1.14%). Year-to-date, ENVB has declined -37.56%, versus a 21.45% rise in the benchmark S&P 500 index during the same period.


About the Author: Manisha Chatterjee


Since she was young, Manisha has had a strong interest in the stock market. She majored in Economics in college and has a passion for writing, which has led to her career as a research analyst. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ENVBGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

2022 Stock Market Outlook

The stock market (SPY) has continued on a bullish path in 2021. Will that continue in 2022? And what could happen to awaken the bear market from hibernation? 40 year investment veteran Steve Reitmeister explores this and more in this early edition of his 2022 Stock Market Outlook. Read on for full details below...

:  |  News, Ratings, and Charts

How Recent Bearish Sentiment Will Impact the Stock Market

Last week, the S&P 500 (SPY) fell during a short trading week. Multiple factors were weighing on investor sentiment. First was September's history for being a weaker month for stock performance. In addition, the previous week's August payrolls miss seemed to linger on investors' minds due to concerns that the delta variant of COVID was slowing the rebound in the economy. The real estate sector led declines as long-term interest rates increased. Consumer staples and utility stocks performed the best. In terms of market cap, the small-cap Russell 2000 Index underperformed the market after two strong weeks of outperforming the larger benchmarks. Growth stocks also outperformed Value stocks. I’ll discuss this and more below…

:  |  News, Ratings, and Charts

How to Turn Low Priced Stocks into BIG Winners?

Some investors are into growth stocks...some prefer value stocks while others are into momentum, income, chart patterns, insider trading and more. But one area that most investors agree upon is the great appeal in buying low priced stocks. Like those under $10 given the potential that prices soar and you easily beat the stock market (SPY). Read on to discover our brand new strategy for selecting low priced stocks that has led to a surprising +62.88% average annual return. Get the rest below...

:  |  News, Ratings, and Charts

3 Growth Stocks You Can Buy at a Reasonable Price

Even with growth stocks falling last week, investors are still pouring money into companies with strong growth potential. When you add in a value component, you get the best of both worlds. That's why investors should consider growth at a reasonable price stocks such as Westlake Chemical Corporation (WLK), ManpowerGroup (MAN), AutoNation, Inc. (AN).

:  |  News, Ratings, and Charts

How to Turn Low Priced Stocks into BIG Winners?

Some investors are into growth stocks...some prefer value stocks while others are into momentum, income, chart patterns, insider trading and more. But one area that most investors agree upon is the great appeal in buying low priced stocks. Like those under $10 given the potential that prices soar and you easily beat the stock market (SPY). Read on to discover our brand new strategy for selecting low priced stocks that has led to a surprising +62.88% average annual return. Get the rest below...

Read More Stories

More Enveric Biosciences Inc. (ENVB) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ENVB News